Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples.

BACKGROUND Ovarian cancer causes more than 15000 deaths per year in the United States. The survival of patients is quite heterogeneous, and accurate prognostic tools would help with the clinical management of these patients. METHODS We developed and validated two gene expression signatures, the first for predicting survival in advanced-stage, serous ovarian cancer and the second for predicting debulking status. We integrated 13 publicly available datasets totaling 1525 subjects. We trained prediction models using a meta-analysis variation on the compound covariable method, tested models by a "leave-one-dataset-out" procedure, and validated models in additional independent datasets. Selected genes from the debulking signature were validated by immunohistochemistry and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) in two further independent cohorts of 179 and 78 patients, respectively. All statistical tests were two-sided. RESULTS The survival signature stratified patients into high- and low-risk groups (hazard ratio = 2.19; 95% confidence interval [CI] = 1.84 to 2.61) statistically significantly better than the TCGA signature (P = .04). POSTN, CXCL14, FAP, NUAK1, PTCH1, and TGFBR2 were validated by qRT-PCR (P < .05) and POSTN, CXCL14, and phosphorylated Smad2/3 were validated by immunohistochemistry (P < .001) as independent predictors of debulking status. The sum of immunohistochemistry intensities for these three proteins provided a tool that classified 92.8% of samples correctly in high- and low-risk groups for suboptimal debulking (area under the curve = 0.89; 95% CI = 0.84 to 0.93). CONCLUSIONS Our survival signature provides the most accurate and validated prognostic model for early- and advanced-stage high-grade, serous ovarian cancer. The debulking signature accurately predicts the outcome of cytoreductive surgery, potentially allowing for stratification of patients for primary vs secondary cytoreduction.

[1]  Benjamin Frederick Ganzfried,et al.  Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. , 2014, Journal of the National Cancer Institute.

[2]  Jinsong Liu,et al.  TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. , 2013, Cancer research.

[3]  G. Omenn,et al.  Evolution of Translational Omics: Lessons Learned and the Path Forward , 2013 .

[4]  Benjamin Haibe-Kains,et al.  curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome , 2013, Database J. Biol. Databases Curation.

[5]  Linlin Tang,et al.  The urokinase plasminogen activator system in breast cancer invasion and metastasis. , 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[6]  J. Erler,et al.  Lysyl oxidase plays a critical role in endothelial cell stimulation to drive tumor angiogenesis. , 2013, Cancer research.

[7]  K. Cibulskis,et al.  Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. , 2012, The Journal of clinical investigation.

[8]  Stephen T. C. Wong,et al.  Microenvironmental regulation of epithelial-mesenchymal transitions in cancer. , 2012, Cancer research.

[9]  R. Brown,et al.  Does tumour biology determine surgical success in the treatment of epithelial ovarian cancer? A systematic literature review , 2012, British Journal of Cancer.

[10]  C. Ricciardelli,et al.  Transforming Growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): A Matrix Protein with Dual Functions in Ovarian Cancer , 2012, International journal of molecular sciences.

[11]  Jie Chen,et al.  SPARC Is a Key Regulator of Proliferation, Apoptosis and Invasion in Human Ovarian Cancer , 2012, PloS one.

[12]  H. Ryu,et al.  Impact of Complete Cytoreduction Leaving No Gross Residual Disease Associated with Radical Cytoreductive Surgical Procedures on Survival in Advanced Ovarian Cancer , 2012, Annals of Surgical Oncology.

[13]  Beth Y Karlan,et al.  Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time. , 2012, Journal of the National Cancer Institute.

[14]  Jean-Pierre Gillet,et al.  Multidrug Resistance–Linked Gene Signature Predicts Overall Survival of Patients with Primary Ovarian Serous Carcinoma , 2012, Clinical Cancer Research.

[15]  John Quackenbush,et al.  Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer , 2012, PloS one.

[16]  R. Carpenter,et al.  Hedgehog pathway and GLI1 isoforms in human cancer. , 2012, Discovery medicine.

[17]  Tatsuhiko Tsunoda,et al.  High-Risk Ovarian Cancer Based on 126-Gene Expression Signature Is Uniquely Characterized by Downregulation of Antigen Presentation Pathway , 2012, Clinical Cancer Research.

[18]  Hong Peng,et al.  Interactions between cancer stem cells and their niche govern metastatic colonization , 2011, Nature.

[19]  N. Brünner,et al.  Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 , 2011, Expert review of molecular diagnostics.

[20]  F. Bertucci,et al.  A seven-gene prognostic model for platinum-treated ovarian carcinomas , 2011, British Journal of Cancer.

[21]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[22]  M. Pencina,et al.  On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data , 2011, Statistics in medicine.

[23]  A. Sood,et al.  Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. , 2011, Neoplasia.

[24]  B. Karlan,et al.  Periostin promotes ovarian cancer angiogenesis and metastasis. , 2010, Gynecologic oncology.

[25]  E. Lengyel,et al.  Ligand independent activation of c-Met by fibronectin and α5β1-integrin regulates ovarian cancer invasion and metastasis , 2010, Oncogene.

[26]  H. Lai,et al.  TGF-β: friend or foe? The role of TGF-β/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy , 2010, Expert opinion on therapeutic targets.

[27]  David M. Simcha,et al.  Tackling the widespread and critical impact of batch effects in high-throughput data , 2010, Nature Reviews Genetics.

[28]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[29]  B. Karlan,et al.  Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  P. Heikkilä,et al.  Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth. , 2010, The American journal of pathology.

[31]  E. Kohn,et al.  Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. , 2010, Cancer research.

[32]  Ituro Inoue,et al.  Gene Expression Profile for Predicting Survival in Advanced-Stage Serous Ovarian Cancer Across Two Independent Datasets , 2010, PloS one.

[33]  S. Koscielny Why Most Gene Expression Signatures of Tumors Have Not Been Useful in the Clinic , 2010, Science Translational Medicine.

[34]  W. Wong,et al.  A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. , 2009, Cancer cell.

[35]  K. Coombes,et al.  Deriving chemosensitivity from cell lines: Forensic bioinformatics and reproducible research in high-throughput biology , 2009, 1010.1092.

[36]  F. Bertucci,et al.  Gene expression profiling and prediction of clinical outcome in ovarian cancer. , 2009, Critical reviews in oncology/hematology.

[37]  R. Bristow,et al.  Predicting the Outcome of Cytoreductive Surgery for Advanced Ovarian Cancer: A Review , 2009, International Journal of Gynecologic Cancer.

[38]  W. Weichert,et al.  A prognostic gene expression index in ovarian cancer—validation across different independent data sets , 2009, The Journal of pathology.

[39]  P. Dijke,et al.  Transforming growth factor-beta signaling and tumor angiogenesis. , 2009, Frontiers in bioscience.

[40]  H. Hollema,et al.  Survival-Related Profile, Pathways, and Transcription Factors in Ovarian Cancer , 2009, PLoS medicine.

[41]  J. Erler,et al.  Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. , 2009, Cancer cell.

[42]  R. Bicknell,et al.  Tumor stroma as a target in cancer. , 2008, Current cancer drug targets.

[43]  R. Tothill,et al.  Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome , 2008, Clinical Cancer Research.

[44]  Laurent Ozbun,et al.  A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. , 2008, Cancer research.

[45]  Kevin R Coombes,et al.  Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  K. Dobbin,et al.  How Large a Training Set is Needed to Develop a Classifier for Microarray Data? , 2008, Clinical Cancer Research.

[47]  Ross S Berkowitz,et al.  Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Ying Chen,et al.  Functional properties and intracellular signaling of CCN1/Cyr61 , 2007, Journal of cellular biochemistry.

[49]  Anil Potti,et al.  An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  György Horvath,et al.  Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. , 2006, European journal of cancer.

[51]  S. Mok,et al.  Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. , 2006, Cancer research.

[52]  J. Quigley,et al.  Matrix metalloproteinases and tumor metastasis , 2006, Cancer and Metastasis Reviews.

[53]  Wing H Wong,et al.  Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. , 2005, Cancer research.

[54]  Wolfgang Viechtbauer,et al.  Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model , 2005 .

[55]  R. Simon,et al.  Development and validation of therapeutically relevant multi-gene biomarker classifiers. , 2005, Journal of the National Cancer Institute.

[56]  M. West,et al.  Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. , 2004, American journal of obstetrics and gynecology.

[57]  R. Kerbel,et al.  Versican/PG‐M G3 domain promotes tumor growth and angiogenesis , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[58]  L. Khachigian Early Growth Response-1: Blocking Angiogenesis by Shooting the Messenger , 2004, Cell cycle.

[59]  J. Tukey Tightening the clinical trial. , 1993, Controlled clinical trials.

[60]  C. Perez,et al.  Principles and Practice of Gynecologic Oncology , 1992 .

[61]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[62]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[63]  Jack L. Vevea,et al.  Fixed- and random-effects models in meta-analysis. , 1998 .

[64]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.